Service Evaluation for Newborn Screening for Spinal Muscular Atrophy
A legfontosabb adatok
- Ki végzi
- University of Oxford
- Hol
- London, Oxford és Warwick (Egyesült Királyság)Mind a 3 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 750 000 fő, tervezett
- Kezdés
- 2026. aug. 1.
- Várható befejezés
- 2031. febr.
- A vizsgálat típusa
- Megfigyeléses, 3 csoport
- A regiszteradat frissítve
- 2026. október 22.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan újszülötteket keres, akiknek a szülei beleegyeznek, hogy a rutin sarokszúrásos szűrés kiegészüljön az SMA szűrésével. Követi azokat a gyerekeket is, akiknél SMA-t találnak, és a szülőket és az egészségügyi dolgozókat is kérdezi a szűrésről.
- Életkor
- 5 napostól 5 évesig
- Nem
- Mindkét nem részt vehet.
- A betegség stádiuma
- Spinális izomatrófia (SMA), genetikailag igazolt diagnózissal, az SMN2 másolatok számától függetlenül. Az újszülötteket még a tünetek megjelenése előtt szűrik.
- Biomarker vagy leletérték
- Genetikailag igazolt SMA diagnózis, az SMN2 másolatok számától függetlenül.
A részvétel fő kizáró okai
- Azok az újszülöttek nem vehetnek részt a szűrésben, akiknek a szülei nem egyeznek bele a szokásos NHS sarokszúrásos újszülöttszűrésbe
- Azok a gyerekek nem vehetnek részt a követésben, akiknél az SMA-t magán újszülöttszűréssel állapították meg
A regiszter feltételei, szó szerint
Mind a 21 feltétel megnézéseKevesebb
Ki vehet részt
- Newborn for SMA screening (and acceptability study); All newborns will be included if:
- Their parent(s)/guardian(s)' consent to the addition of SMA screening
- Their DBS card will be processed at a screening centre that has been opened for SMA screening
- If They are born between October 2026 and September 2030; For the acceptability study the parent(s)/guardian(s) of newborns (see criteria above) will be included whether they accept or decline screening; SMA patients for follow up (and acceptability study); If the patient is diagnosed with SMA by Standard of care route, they are included if they:
- Have a confirmed genetic diagnosis of SMA, regardless of SMN2 copies
- Are born between October 2024 and July 2026 inclusive (Cohort 0)
- Are born between August 2026 and September 2027 inclusive before SMA NBS has been initiated at the NBS testing centre covering their region of birth (Cohort 1a)
- Undergo SMA testing due to symptom onset or family history of SMA (but not through private SMA NBS); If the patient is diagnosed with SMA through NBS, they are included if they:
- Have a confirmed genetic diagnosis of SMA, regardless of SMN2 copies
- At the time of their birth, SMA NBS has been initiated at the NBS testing centre covering their region of birth
- Are born between October 2026 and November 2027 inclusive (Cohort 1b)
- Are born between December 2027 and September 2028 inclusive (Cohort 2a)
- Are born between October 2028 and March 2029 inclusive and have 3 SMN2 copies (Cohort 2b)
- Are born between April 2029 and September 2030 inclusive (follow-up cohort)
- Undergo SMA testing due to NBS, family history of SMA or symptom onset (If screening was not done regardless of the reason or if screening is a false negative); Parent(s)/guardian(s) of babies with a negative SMA screening result (acceptability study only) If their baby is born between October 2026 and March 2029 within a region covered by one of the 7 screening laboratories at the time of birth; Healthcare Professionals (acceptability study only)
- If they are involved in the delivery of SMA screening or supporting families following a screening result (if one of the areas covered by SMA screening)
- Or, they support babies and families following SoC diagnosis
- If they are a member of SMA UK staff involved in providing support/guidance to families who receive an SMA diagnosis
Ki nem vehet részt
- Newborn for SMA screening; Newborns will be excluded from the study if:
- Their parent(s)/guardian(s) do not consent to standard NHS NBS and therefore the heel prick test (Parent(s)/guardian(s) who decline standard NHS NBS will still be invited to take part in the acceptability study); SMA patients for follow up; Patients with SMA will be excluded from the study if:
- They are diagnosed due to private newborn screening
Helyszínek itt: Egyesült Királyság
- Kings College LondonLondon, Egyesült KirályságContact: Jane ChudleighRésztvevőt keres
- University of OxfordOxford, Egyesült KirályságContact: Laura ChivertonToborzás még nem indult
- Warwick UniversityWarwick, Egyesült KirályságContact: Felicity BoardmanRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
Spinal Muscular Atrophy (SMA) is a disease that causes progressive muscle weakness. There are many types- the most severe and most common, type 1, affects very young babies, and is life-threatening if untreated. Other types can cause significant disability. Most cases are caused by a missing part of the survival motor neuron 1 (SMN1) gene. Another related gene, SMN2, can partially compensate for this affected gene. With more copies of SMN2 broadly leading to a milder disease.
A teljes eredeti leírásKevesebb
Three new treatments can slow or prevent symptoms, but they work best when given before symptoms appear. This has led to many countries, including the USA and much of Europe, introducing newborn screening (NBS) for SMA, so that affected babies can be treated as early as possible. The investigators ran a UK pilot project that screened nearly 33,000 babies and found the test to be accurate and practical, but this pilot was too small to show whether screening improves outcomes or is good value for money for the NHS. The UK National Screening Committee would also like to know how acceptable NBS for SMA is for different groups of people. This study is designed to answer those questions.
Screening will be introduced across seven NHS screening laboratories, most of which already screen for another rare condition, severe combined immunodeficiency (SCID). About 400,000 babies are born in the areas covered by these laboratories every year. Screening will be introduced gradually, so that the investigators can compare babies born before and after screening starts, with screening between the autumn of 2026 and autumn 2027.
This will be followed by a period of only SMA NBS which will continue until autumn 2030. This will be compared to a period of no screening from autumn 2024 until autumn 2027 to include babies born before any laboratory starts screening and where the screening laboratories have not yet opened during the study.
The study has two phases:
Phase 1 will examine how successfully SMA NBS can be delivered through the NHS, and will look at:
* Whether screening can accurately identify SMA * How quickly screening results are returned * Whether babies diagnosed through SMA NBS start treatment earlier than those diagnosed because of symptoms * How many parent(s)/guardian(s)/guardians agree to take part in screening * How different groups feel about SMA NBS and whether there are any areas of the process that need to be improved
Phase 2 will examine whether SMA NBS improves children's lives and will look at:
* Longer-term health outcomes, including whether treated children with SMA diagnosed by NBS or standard of care (SoC) can walk independently by 24 months * Quality of life for children and families with SMA diagnosed by NBS or SoC * Evaluate overall costs and benefits for the NHS
How will the study work?
* It will be led by the University of Oxford, with input from hospitals, laboratories, patient groups, and experts across the UK. * Parent(s)/guardian(s) will be asked for consent when their baby has the routine heel-prick blood test. No extra blood will be needed. * A national clinical network called SMA REACH, will provide information about the milestones babies reach and their general health. * All other information will be asked for directly from parent(s)/guardian(s) with children who have SMA * Health economists will use information collected to update an existing mathematical model on cost-effectiveness. This will estimate whether the benefits of early diagnosis and treatment outweigh the costs of screening.
The study will give the UK National Screening Committee (UK NSC) clear, high-quality evidence on whether newborn screening for SMA is feasible, acceptable, beneficial for children and families, and good value for the NHS.
A vizsgálat 3 csoportja
- Phase 0
Patients with SMA who were born between October 2024 and August 2026 and were not offered newborn screening
- Phase 1
Stepped-wedge study with a newborn screening laboratory opening every two months to offer SMA newborn screening. This will be across seven newborn screening laboratories.
- Phase 2
Patients who have been identified as screen positive for SMA will be invited into a follow up study.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
- A regiszteradat frissítve
- 2026. október 22.